Portage Biotech Inc. (NASDAQ:PRTG) Sees Large Decrease in Short Interest

Portage Biotech Inc. (NASDAQ:PRTG) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 14,000 shares, a decrease of 74.5% from the June 15th total of 54,900 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 732,100 shares, the short-interest ratio is presently 0.0 days.

Portage Biotech Stock Up 6.1 %

Shares of NASDAQ PRTG traded up $0.01 on Thursday, hitting $0.18. The company had a trading volume of 791,324 shares, compared to its average volume of 397,457. Portage Biotech has a 12-month low of $0.13 and a 12-month high of $3.95. The business has a 50 day moving average of $0.25 and a two-hundred day moving average of $0.55. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.20 million, a P/E ratio of -0.02 and a beta of 1.47.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.